Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Nov 13:9:1259.
doi: 10.3389/fphar.2018.01259. eCollection 2018.

Cannabinoids and Pain: New Insights From Old Molecules

Affiliations
Review

Cannabinoids and Pain: New Insights From Old Molecules

Sonja Vučković et al. Front Pharmacol. .

Abstract

Cannabis has been used for medicinal purposes for thousands of years. The prohibition of cannabis in the middle of the 20th century has arrested cannabis research. In recent years there is a growing debate about the use of cannabis for medical purposes. The term 'medical cannabis' refers to physician-recommended use of the cannabis plant and its components, called cannabinoids, to treat disease or improve symptoms. Chronic pain is the most commonly cited reason for using medical cannabis. Cannabinoids act via cannabinoid receptors, but they also affect the activities of many other receptors, ion channels and enzymes. Preclinical studies in animals using both pharmacological and genetic approaches have increased our understanding of the mechanisms of cannabinoid-induced analgesia and provided therapeutical strategies for treating pain in humans. The mechanisms of the analgesic effect of cannabinoids include inhibition of the release of neurotransmitters and neuropeptides from presynaptic nerve endings, modulation of postsynaptic neuron excitability, activation of descending inhibitory pain pathways, and reduction of neural inflammation. Recent meta-analyses of clinical trials that have examined the use of medical cannabis in chronic pain present a moderate amount of evidence that cannabis/cannabinoids exhibit analgesic activity, especially in neuropathic pain. The main limitations of these studies are short treatment duration, small numbers of patients, heterogeneous patient populations, examination of different cannabinoids, different doses, the use of different efficacy endpoints, as well as modest observable effects. Adverse effects in the short-term medical use of cannabis are generally mild to moderate, well tolerated and transient. However, there are scant data regarding the long-term safety of medical cannabis use. Larger well-designed studies of longer duration are mandatory to determine the long-term efficacy and long-term safety of cannabis/cannabinoids and to provide definitive answers to physicians and patients regarding the risk and benefits of its use in the treatment of pain. In conclusion, the evidence from current research supports the use of medical cannabis in the treatment of chronic pain in adults. Careful follow-up and monitoring of patients using cannabis/cannabinoids are mandatory.

Keywords: animals; cannabis/cannabinoids; efficacy; humans; pain; pharmacodynamics; pharmacokinetics; safety.

PubMed Disclaimer

References

    1. Abrams D. I., Couey P., Shade S. B., Kelly M. E., Benowitz N. (2011). Cannabinoid-opioid interaction in chronic pain. Clin. Pharmacol. Ther. 90 844–851. 10.1038/clpt.2011.188 - DOI - PubMed
    1. Abrams D. I., Guzman M. (2015). Cannabis in cancer care. Clin. Pharmacol. Ther. 97 575–586. 10.1002/cpt.108 - DOI - PubMed
    1. Adamson Barnes N. S., Mitchell V. A., Kazantzis N. P., Vaughan C. W. (2016). Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine neuropathic pain model. Br. J. Pharmacol. 173 77–87. 10.1111/bph.13337 - DOI - PMC - PubMed
    1. Agurell S., Halldin M., Lindgren J. E., Ohlsson A., Widman M., Gillespie H., et al. (1986). Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol. Rev. 38 21–43. - PubMed
    1. Ahn K., Smith S. E., Liimatta M. B., Beidler D., Sadagopan N., Dudley D. T., et al. (2011). Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain. J. Pharmacol. Exp. Ther. 338 114–124. 10.1124/jpet.111.180257 - DOI - PMC - PubMed

LinkOut - more resources